Overview

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Status:
Unknown status
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
Phase:
Phase 1
Details
Lead Sponsor:
Synta Pharmaceuticals Corp.